Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News NextCure brings Simcere Zaiming’s SIM0505 to U.S. trials as ADC race accelerates in oncology Find out how NextCure and Simcere Zaiming are expanding SIM0505’s Phase 1 program into the U.S. and redefining the future of ADC collaboration. bySoujanya RaviOctober 16, 2025